- Brain Tumors
- Support Services
- Take Action
- About Us
Uniquely poised to drive change and progress throughout the drug discovery and development pipeline, our initiatives and programs further knowledge and deliver results to our community.
Our flagship research initiative, the DDR Consortium, brings together a diverse team of renowned adult and pediatric researchers to rapidly advance a new class of promising potential treatments.
GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is the world’s first “adaptive clinical trial platform.” The purpose is to evaluate multiple investigational treatments for either newly diagnosed or recurrent glioblastoma to determine if any of these study treatment(s) improve overall survival as compared to standard treatments.
See All News